MRK
Merck & Co. Inc.
$111.38
-0.82%
2026-05-08
About Merck & Co. Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Key Fundamentals
P/E Ratio
31.67
Forward P/E
11.81
EPS (TTM)
$3.55
ROE
18.9%
Revenue Growth (YoY)
4.9%
Profit Margin
13.6%
Debt/Equity
106.94
Dividend Yield
3.0%
Price/Book
5.29
Beta
0.20
Market Cap
$277.66B
Avg Volume (10D)
9.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$125.14
60D Low
$107.90
Avg Volume
8.4M
Latest Close
$111.38
Get breakout alerts for MRK
Sign up for Breakout Scanner to receive daily notifications when MRK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Merck & Co. Inc. (MRK) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors MRK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MRK operates in the Healthcare sector within the Drug Manufacturers - General industry. Data is provided for informational purposes only and does not constitute financial advice.